Please check your internet connection and try again.
# Sodium Phosphate Enema
## Overview
Sodium phosphate enema is a saline osmotic laxative. It works by drawing water into the colon, increasing internal pressure to stimulate peristalsis and evacuation. Its onset of action is typically 2–15 minutes.
## Primary Indications
* Relief of occasional constipation.
* Bowel preparation prior to rectal examination or endoscopic procedures.
## Adult Dosing
* **Standard dose:** 118 mL (one ready-to-use bottle) administered rectally as a single dose in a 24-hour period. Do not exceed one dose per day.
## Pediatric Dosing
* **Children 2 to 11 years:** 59 mL (pediatric size) administered rectally as a single dose in a 24-hour period.
* **Children <2 years:** Generally contraindicated due to the high risk of electrolyte disturbances (hyperphosphatemia, hypocalcemia).
## Dose Adjustments
* **Renal Impairment:** Use with extreme caution. Significant risk of severe hyperphosphatemia, hypocalcemia, hypernatremia, and hypokalemia. Avoid in patients with clinically significant renal insufficiency.
* **Hepatic Impairment:** No specific dosing adjustments, but monitor for fluid/electrolyte imbalance.
## Contraindications
* Hypersensitivity to sodium phosphates.
* Megacolon (congenital or acquired).
* Gastrointestinal obstruction or perforation.
* Active inflammatory bowel disease (e.g., ulcerative colitis).
* Presence of congestive heart failure, bowel obstruction, or active anorectal disease/fissures.
## Adverse Effects
* **Common:** Rectal irritation, abdominal cramping, nausea/vomiting.
* **Severe:** Severe electrolyte imbalances (hyperphosphatemia, hypocalcemia, hypernatremia), dehydration, acute phosphate nephropathy, rectal mucosal injury or perforation.
## Key Drug Interactions
* **Diuretics:** May exacerbate potential for dehydration and electrolyte abnormalities.
* **ACE inhibitors/ARBs/NSAIDs:** Concurrent use may increase the risk of acute phosphate nephropathy in susceptible patients.
* **Calcitonin/Bisphosphonates:** Risk of additive hypocalcemia.
## Monitoring
* Monitor for signs of dehydration (thirst, dry mucous membranes, decreased urine output).
* In vulnerable populations, monitor serum electrolytes (phosphate, calcium, potassium, sodium) and renal function (BUN/SCr).
* Ensure patient comfort; discontinue if significant resistance is felt during insertion.
## Clinical Pearls
* **Administration:** Patient should lie on the left side with the right knee bent (Sims' position). Do not force the tip into the rectum.
* **Warning:** Chronic use may lead to laxative dependence and electrolyte depletion.
* **Safety:** Do not use if the patient is on a phosphate-restricted diet.
* **Volume:** Ensure the volume administered matches the weight/age-appropriate product (pediatric vs. adult units).
***
*Disclaimer: This information is for educational purposes only. Clinical guidelines and prescribing protocols vary. Always verify current prescribing information, institutional protocols, and patient-specific factors before administration.*
